Aardvark Therapeutics (AARD) Cash & Equivalents (2024 - 2026)

Aardvark Therapeutics has reported Cash & Equivalents for 3 years, with the latest figure at $91.2 million in Q1 2026.

• Quarterly Cash & Equivalents fell 39.72% year-over-year to $91.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $91.2 million (down 39.72% YoY) and the FY2025 annual result came in at $47.1 million, down 23.67% from the prior year.
• Cash & Equivalents advanced to $91.2 million in Q1 2026 per AARD's latest filing, from $47.1 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $151.3 million in Q1 2025 and troughed at $47.1 million in Q4 2025.
• A 3-year average of $103.2 million and a median of $108.8 million in 2025 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2025 and 2026: Cash & Equivalents fell 23.67% in 2025, then tumbled 39.72% in 2026.
• Over 3 years, Cash & Equivalents stood at $61.6 million in 2024, then dropped by 23.67% to $47.1 million in 2025, then surged by 93.83% to $91.2 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $91.2 million, $47.1 million, and $126.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.